WP
PRQR icon

Woodline Partners’s ProQR Therapeutics PRQR Stock Holding History

Woodline Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.1M Buy
+3,277,143
New +$5.4M 0.02% 643
2025
Q4 		– Sell
-92,140
Closed -$196K – 1097
2025
Q3 		$196K Sell
92,140
-1,411,860
-94% -$3.08M ﹤0.01% 863
2025
Q2 		$3.07M Buy
1,504,000
+178,345
+13% +$290K 0.02% 653
2025
Q1 		$1.76M Sell
1,325,655
-2,231,346
-63% -$4.75M 0.01% 683
2024
Q4 		$9.43M Buy
+3,557,001
New +$11.3M 0.06% 358

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Woodline Partners's PRQR Position: Q2 2026 in Review

Woodline Partners opened a new position in ProQR Therapeutics (PRQR) in Q2 2026: 3,277,143 shares worth $6.1M. The stake represents 0.02% of the portfolio and ranks #643 among its holdings. This is a return to the name: Woodline Partners previously reported a position in PRQR as recently as Q3 2025.

Woodline Partners first reported a position in PRQR in Q4 2024 and has held it in 5 quarters since. The position peaked at $9.43M in Q4 2024. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Woodline Partners held 3,277,143 shares of ProQR Therapeutics worth $6.1M as of Q2 2026.
  • ProQR Therapeutics was a new Woodline Partners position in Q2 2026.
  • ProQR Therapeutics made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #643 holding.
  • Woodline Partners first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Woodline Partners's ProQR Therapeutics position peaked at $9.43M in Q4 2024.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.